企業プロフィール
bioAffinity Technologies, Inc. 株価・ニュース・カタリスト
- ティッカー:
- BIAF
- 取引所:
- NASDAQ
- セクター:
- MedTech
- 所在地:
- United States
株価パフォーマンス
0.39 USD (-2.51%)
終値
最終更新: 2026年8月17日
7.62M USD
時価総額
株価変動の要因
The latest monitored company update is “bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung.” The corresponding closing-price reaction is not yet available.
企業概要
Noninvasive Lung Diagnostics
bioAffinity Technologies develops noninvasive tests for the early detection and characterization of lung disease. Its approach uses flow-cytometry and artificial-intelligence analysis of cells collected from sputum samples.
CyPath Lung
CyPath Lung is a laboratory-developed test intended to help assess patients at elevated risk of lung cancer, including those with indeterminate imaging findings. It is positioned between imaging surveillance and invasive diagnostic procedures. The company is also exploring applications of its cellular-analysis platform in asthma and chronic obstructive pulmonary disease, including potential companion-diagnostic uses.
今後のカタリスト
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。